AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has failed to improve overall survival (OS) in ...

“As a company driven by science and patient-centricity, AstraZeneca stands in full support of this ... He said he hoped that ...

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

On Friday, the Federal Trade Commission (FTC) filed a formal complaint against three major pharmacy benefit managers ...

Two of the simplest ways to measure the success of companies that develop and commercialize drugs is to count their approvals ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right ... selling on individual US-listed stocks […] A Phase 3 ...

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Common medicines used to treat conditions including heartburn, reflux, indigestion and stomach ulcers may be the subject of a ...

The recent GST cut on cancer drugs could mean significant cost reductions for cancer treatment in India. Read to know how it ...